@FierceMedDev: Here's our latest FierceDiagnostics, with news on concussion biomarkers, autism tests and more. Newsletter | Follow @FierceMedDev
@MarkHFierce: A European VC firm is raising $ for a new fund that will target, in part, Dx and device companies. Story | Follow @MarkHFierce
@MichaelGFierce: NASA tech makes space-age microcapsules for cancer drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Good news for chocolate lovers: Bacteria in the gut can eat up cocoa and turn it into compounds that help the heart. Article | Follow @EmilyWFierce
> Nanosphere ($NSPH), a molecular diagnostics developer, will sell up to $30 million of its common stock to shareholder Aspire Capital. Release
> Medical device makers are warning that tighter regulations in Europe could push their development work away from the region and to countries such as China. Story
> California's Aurora Spine said a surgeon in Poland has performed the first surgical procedure there involving its new spinal fusion implant. Release
> Trovagene will work with the Catholic Health Initiatives Center for Translational Research to test the usefulness of the company's urine-based cell-free DNA cancer monitoring tests in clinical practice. Release
> A number of new companies in the U.S., Europe and Japan are developing bionic suits that could, in part, help aging and disabled patients care for themselves. Story
Biotech News
@FierceBiotech: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer. Story | Follow @FierceBiotech
@JohnCFierce: Bristol-Myers partner Alder Bio looking for $115M IPO haul - clazakizumab and migraine drug ALD403. More | Follow @JohnCFierce
@DamianFierce: Proteon sets out on its own after Novartis waves off a $550M deal. News | Follow @DamianFierce
@GalenMoore: Exact Sciences' at-home test for colon cancer is nearly as effective as a colonoscopy. Read more at Bloomberg | Follow @GalenMoore
> The FDA vs. the flash mob: Hard questions as parents demand unproven drugs. More
> A renal cancer study fails and stock plunges, but Bionomics stays upbeat. Story
Pharma News
@FiercePharma: Statins and muscle aches are unrelated. Story | Follow @FiercePharma
@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Article | Follow @TracyStaton
@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce
> Tamiflu study funded by Roche shows lives saved in pandemic. More
> Roche breast cancer drugs Perjeta, Kadcyla are built for speed, report finds. Item
> Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use. Piece
Drug Delivery News
> MedImmune inks licensing deal with Bioasis for brain delivery platform. News
> GenSpera enrolls brain cancer mid-stage trial with 'grenade' delivery. Story
> NASA tech makes space-age microcapsules for cancer drug delivery. Story
> Harvard scientists fold DNA to make cages for drug delivery. Article
> CeloNova wins a U.S. exemption trial for its nano-coated stent. News
> Oral drugs derived from snail venom could offer less invasive pain management. Brief
Diagnostics News
> Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth. Story
> SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests. News
> Quanterix diagnostic spotted a key concussion biomarker in blood. Article
> Is diagnostics maker Corgenix looking to sell itself? Story
> For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech. Story
> Federal funding drops are forcing layoffs at the Broad Institute's genome sequencing arm. Brief
Pharma Marketing News
> They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions. Report
> Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Story
> McKinsey's four drug launch flavors: Good, bad, ugly and misguided. Story
> Pfizer's impressive Prevnar data isn't enough to win billions in adult sales. Analysis
> For once, the FDA writes up pharma for a simple Facebook violation. News
> Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic. Brief